Covered recipient · General Payments record
IYAD S HAMARNEH
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,725.09
78 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,626.09 | 77 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
IYAD S HAMARNEH
NPI 1427268259 · CMS profile ID 109889
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PRESCOTT, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- IYAD S HAMARNEH, NPI 1427268259, CMS profile ID 109889, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1427268259?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
78 matching records · $1,725.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–78 of 78.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | $13.25 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145530865 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.25 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101641346 | CMS |
| PFIZER INC. | $17.63 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131413876 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.45 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086189216 | CMS |
| Aveo Pharmaceuticals, Inc. | $99.00 | 04/29/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143478898 | CMS |
| Incyte Corporation | $26.54 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141177680 | CMS |
| PFIZER INC. | $21.85 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131311738 | CMS |
| Janssen Biotech, Inc. | $23.10 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078281155 | CMS |
| Genentech USA, Inc. | $22.37 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133023099 | CMS |
| ABBVIE INC. | $21.04 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103868341 | CMS |
| Celgene Corporation | $20.99 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101166714 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.88 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101641328 | CMS |
| ARRAY BIOPHARMA INC | $20.15 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131404029 | CMS |
| Genmab U.S., Inc. | $26.01 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126827352 | CMS |
| Karyopharm Therapeutics Inc. | $13.29 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145530862 | CMS |
| Mirati Therapeutics, Inc. | $13.45 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117173910 | CMS |
| Pharmacosmos Therapeutics Inc. | $25.07 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154822259 | CMS |
| ABBVIE INC. | $19.20 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103868339 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.66 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101641254 | CMS |
| Genmab U.S., Inc. | $27.45 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126827346 | CMS |
| PFIZER INC. | $20.39 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131283893 | CMS |
| PFIZER INC. | $17.81 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131141182 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.70 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101641250 | CMS |
| Celgene Corporation | $16.89 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101166704 | CMS |
| Incyte Corporation | $18.77 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141253036 | CMS |
| PFIZER INC. | $22.74 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130982331 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.86 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104369513 | CMS |
| Blueprint Medicines Corporation | $21.38 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147441042 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $576,327.32 | 246 |
| PY2024 | Principal investigator | $206,411.16 | 53 |
| PY2023 | Principal investigator | $55,000.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
246 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,493.36 | 12/31/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185555699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387989 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388007 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388025 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 12/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363539 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 12/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363567 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387975 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $66.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387977 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,630.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387979 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $64.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387981 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387983 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387985 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387987 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387991 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387993 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387995 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387997 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387999 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388001 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388003 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388005 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $59.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388009 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388011 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388013 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388015 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388017 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388019 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388021 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $53.00 | 12/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388023 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $56.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363531 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363535 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363541 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363543 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363545 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363547 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $383.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363549 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,808.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363553 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,808.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363555 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,514.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363561 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363565 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363569 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363571 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $36.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363573 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363575 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363579 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363581 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363585 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,336.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 11/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 11/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 11/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 10/30/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387947 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223363383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 10/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 10/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363559 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 10/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363563 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 10/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228726424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387927 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387929 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387931 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13,320.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387933 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387935 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387937 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387939 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387941 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387943 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387945 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387949 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387951 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387953 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387955 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387957 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387959 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387961 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387963 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387965 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387967 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $450.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387969 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387971 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 10/09/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387973 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387889 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $301.00 | 09/25/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387915 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387869 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387891 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387901 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387903 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387909 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387911 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 09/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387913 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/15/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228757764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 09/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387863 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 09/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387879 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 09/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387897 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 09/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387899 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 09/11/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387907 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387865 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387871 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387873 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387875 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387877 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $301.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387881 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387883 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387885 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387887 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387893 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387895 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387905 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $301.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387917 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $90.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387919 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387921 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387923 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 09/04/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387925 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,150.00 | 08/31/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185555703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387851 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387853 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387855 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387857 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $47.00 | 08/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387861 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,656.00 | 08/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387859 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 07/18/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387419 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 07/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745450 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,300.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185555705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 06/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 06/16/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363469 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 06/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 06/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363529 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 06/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 06/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/28/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363483 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/28/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363485 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 05/28/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228772944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363479 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363481 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363515 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363519 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363523 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363525 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.00 | 05/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363527 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/12/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363509 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 05/12/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363511 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $28,500.00 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185555691 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,712.05 | 05/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185555697 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,650.00 | 04/30/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185555695 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,834.75 | 04/30/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185555701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13,320.00 | 04/24/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387845 |
| Principal investigator 1 | Eli Lilly and Company | $1,110.00 | 04/22/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187893530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387833 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387835 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387837 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387839 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387841 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387843 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387847 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,304.00 | 04/17/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387849 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223363381 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,204.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363453 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363493 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363505 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363507 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.00 | 04/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363521 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 04/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228747077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363475 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 04/14/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363477 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,000.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/27/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/25/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363405 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/25/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387815 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 03/20/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387817 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 03/20/2025 | Non-covered Recipient Entity UNITED STATES ONCOLOGY RESEARCH LLC | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | No dispute reported | 06/30/2026 | 1211676384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $201.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $201.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $201.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,906.00 | 03/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387819 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $555.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387823 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387825 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,242.00 | 03/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387827 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387821 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387829 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,310.00 | 03/06/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223387831 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/04/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 03/04/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363387 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 02/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363443 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,125.00 | 02/13/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223387187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/12/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 02/12/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363403 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,400.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185555693 |
| Principal investigator 1 | Eli Lilly and Company | $60,941.00 | 02/04/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187892746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/23/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363399 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/23/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363445 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,934.25 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | No dispute reported | 06/30/2026 | 1185555707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,415.00 | 01/16/2025 | Non-covered Recipient Entity US Oncology Inc | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223388275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U304 | No dispute reported | 06/30/2026 | 1223363379 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $956.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,514.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,914.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $418.00 | 01/15/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363435 |
| Principal investigator 1 | Eli Lilly and Company | $3,066.00 | 01/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC HOPE | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187874935 |
| Principal investigator 1 | Eli Lilly and Company | $92,451.00 | 01/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC HOPE | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187877169 |
| Principal investigator 1 | PFIZER INC. | $957.00 | 01/15/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228745721 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/06/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363385 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $0.01 | 01/06/2025 | Non-covered Recipient Entity Arizona Oncology Associates | DS1062-A-U303 | No dispute reported | 06/30/2026 | 1223363391 |
| Principal investigator 1 | Eli Lilly and Company | $0.73 | 01/06/2025 | Non-covered Recipient Entity ARIZONA ONCOLOGY ASSOCIATES PC HOPE | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187876891 |